This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

A Study of SerpinPC in Participants With Hemophilia B (HemB) With Inhibitors (PRESent-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05789537
Recruitment Status : Recruiting
First Posted : March 29, 2023
Last Update Posted : November 8, 2023
Centessa Pharmaceuticals plc
Information provided by (Responsible Party):
ApcinteX Ltd

Brief Summary:
The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetic (PK) profile of prophylactic SerpinPC in participants with Hemophilia B with inhibitors, as part of the SerpinPC registrational program.

Condition or disease Intervention/treatment Phase
Hemophilia B With Inhibitor Hemophilia B Drug: SerpinPC Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Hemophilia B With Inhibitors
Actual Study Start Date : July 28, 2023
Estimated Primary Completion Date : September 8, 2025
Estimated Study Completion Date : October 28, 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Protein C

Arm Intervention/treatment
Experimental: SerpinPC
Participants will receive SerpinPC 1.2 milligrams/kilogram (mg/kg) subcutaneous (SC) injection every 2 weeks (Q2W) for 48 weeks after a prospective observation of 12 weeks for all participants, either in a prior non-interventional study (AP-0105[NCT05605678]) or as part of the ongoing study observational period.
Drug: SerpinPC
Administered as SC injection.
Other Name: Activated Protein C (APC) inhibitor

Primary Outcome Measures :
  1. Annualized Bleeding Rate (ABR) for Treated Bleeds up to Week 24 [ Time Frame: Up to Week 24 ]

Secondary Outcome Measures :
  1. Annualized Bleeding Rate (ABR) for Treated Bleeds Up to Week 48 [ Time Frame: Up to Week 48 ]
  2. Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds [ Time Frame: Up to Week 48 ]
  3. Annualized Bleeding Rate (ABR) for Treated Spontaneous Joint Bleeds [ Time Frame: Up to Week 48 ]
  4. Total Coagulation Factor and/or Bypass Product Consumption During SerpinPC Treatment [ Time Frame: Up to Week 48 ]
  5. Pharmacokinetic Concentrations of SerpinPC [ Time Frame: From Day 1(Pre-dose) up to Week 48(Post-dose) ]
  6. Haemophilia Quality-of-Life Questionnaire for Adults (Haem-A-QoL) Physical Health Scale [ Time Frame: From Baseline up to Week 48 ]
    The Haem-A-QoL instrument contains 44 items across 10 domains relevant to HRQoL in adults (physical health, feelings, view of participant's self, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership, and sexuality). Each item is rated on a 5-point scale (1=never, 2=rarely, 3=sometimes, 4=often, 5=all the time). Higher scores are indicative of greater impairment in HRQoL.

  7. Number of participants with Adverse events (AEs) [ Time Frame: From Baseline up to Week 52 ]
  8. Number of Participants with Persistent High-titer Antidrug Antibodies (ADAs) [ Time Frame: From Baseline up to Week 48 ]
  9. Number of Participants with Severity of Injection-site Reactions [ Time Frame: Baseline up to Week 44 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male participants greater than or equal to (>=) 12 and less than or equal to (<=) 65 years of age at the time of informed consent.
  2. Capable of providing written informed consent (adolescent assent and parental/guardian/legal representative consent when appropriate) for participation and having the opportunity to discuss the study with the Investigator or delegate.
  3. Historically documented HemB (defined as factor IX <=0.05 international unit/Milliliter (IU/mL) [<=5 percent (%)]).
  4. Participants who are currently in a prophylaxis program must be willing to stop prophylaxis (including episodic prophylaxis for sporting events) before the first dose of SerpinPC.
  5. Historical or ongoing Factor IX inhibitor with bypass agents based on medical records or laboratory reports.
  6. Documented ABR of 6 in the 12 months before screening (participants not on prophylaxis regimen) or documented ABR of ≥2 for participants on prophylaxis regimen
  7. At least 12 weeks of prospective documentation of bleeding episodes in the AP-0105 (NCT05605678) non-interventional study before SerpinPC dosing, or willing to complete a 12-week observational period (at minimum) in AP-0103.
  8. No bleeding in the 7 days before Baseline (the prospective observation period can be extended by 10 days if there is an ongoing active bleed).
  9. D-dimer of <=750 micrograms/Liter (mc/L); in cases where there is a resolving bleed, the exclusion threshold is <=1750 mg/L at Screening and Pre-dosing visits.
  10. Adequate hematologic function, defined as a platelet count of >=100,000/microliters (mcL) (>=100*10^9/L) and hemoglobin level of >=10 grams/deciliter(g/dL) (>=100 g/L or >= 6.206 millimoles per liter (mmol/L) at Screening and Pre-dosing visits.
  11. Adequate hepatic function, defined as a total bilirubin level of <=1.5*upper limit of normal (ULN) (excluding Gilbert syndrome) and aspartate aminotransferase and/or alanine aminotransferase of <=3*ULN at Screening and Pre-dosing visits; no clinical signs or known laboratory or radiographic evidence consistent with cirrhosis of the liver.
  12. Adequate renal function, defined as a serum creatinine level of <=2.0*ULN at Screening and Pre-dosing visits.
  13. Able to use a diary to document bleeding events and medication usage.
  14. Sexually active participants with a partner who could become pregnant should agree to use effective contraception for the duration of the study.

Effective contraceptive measure include condom with or without spermicide, a combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods), vasectomy, partner using stable contraceptive measures (combined [ estrogen and progestogen-containing] hormonal contraception or progestogen-only hormonal contraception initiated 2 or more menstrual cycles prior to screening, intrauterine device [IUD]. Intrauterine hormone-releasing system [IUS], bilateral tubal ligation), and/or sexual abstinence.

Exclusion Criteria:

  1. Known severe thrombophilia (defined as antithrombin deficiency and/or protein S deficiency and/or protein C deficiency).
  2. Participant with previous factor IX inhibitor who responded to immune tolerance induction and remains on prophylactic factor concentrate.
  3. Previous deep vein thrombosis, pulmonary embolism, myocardial infarction, or stroke.
  4. History of intolerance to SC injections.
  5. Uncontrolled hypertension (systolic blood pressure >160 millimeter of mercury (mm Hg); diastolic blood pressure >100 mm Hg).
  6. Weight >150 kilograms (kg) OR body mass index >40 kg/meter square (m^2).
  7. Has active cancer and/or requires therapy for cancer, except for basal cell carcinoma.
  8. Participation in another clinical trial (except for AP-0105 [NCT05605678]) during the 30 days before screening.
  9. Prior, ongoing, or planned treatment with gene therapy for HemB
  10. Any major medical, psychological, or psychiatric condition that could cause the participant to be unsuitable for the study or could interfere with the interpretation of the study results.
  11. History of or other evidence of recent alcohol or drug abuse as determined by the Investigator (in the 12 months before screening).
  12. Known human immunodeficiency virus (HIV) infection with CD4 count (or T-cell count) of <200 cells/mcL within 24 weeks before Screening and Pre-dosing visits. Patients with HIV infection who have CD4 > 200 and meet all other criteria are eligible.
  13. Current or planned treatment with anticoagulant or antiplatelet drugs
  14. Is planning to donate/bank sperm during SerpinPC treatment AND within 30 days of last dose of SerpinPC.
  15. Any other significant conditions or comorbidities that, in the opinion of the Investigator, would make the participant unsuitable for enrollment, or could interfere with participation in, or completion of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05789537

Layout table for location contacts
Contact: Centessa Pharmaceuticals 617-468-5770

Layout table for location information
Centre of Haematology named after prof. R. O. Yeolian/ Hemophilia center Recruiting
Yerevan, Armenia, 0014
Contact: Heghine Khachatryan         
Australia, New South Wales
Royal Prince Alfred Hospital Recruiting
Camperdown, New South Wales, Australia, 2050
Contact: Liane Khoo         
Australia, Victoria
The Alfred Hospital Recruiting
Melbourne, Victoria, Australia, 3004
Contact: Huyen Tran         
Hopital Bicetre Not yet recruiting
Le Kremlin-Bicêtre, France, 94270
Contact: Roseline d'Oiron         
Hospital Universitario La Paz Not yet recruiting
Madrid, Spain, 28046
Contact: María Teresa Álvarez Román         
Taichung Veterans General Hospital Not yet recruiting
Taichung city, Taiwan, 407
Contact: Jiaan-Der Wang         
Chung Shan Medical University Recruiting
Taichung, Taiwan, 40201
Contact: Te-Fu Weng         
China Medical University Hospital Recruiting
Taichung, Taiwan, 40447
Contact: Ching-Tien Peng         
Sponsors and Collaborators
ApcinteX Ltd
Centessa Pharmaceuticals plc
Layout table for additonal information
Responsible Party: ApcinteX Ltd Identifier: NCT05789537    
Other Study ID Numbers: AP-0103
2022-502881-25-00 ( Other Identifier: EU CT Number )
First Posted: March 29, 2023    Key Record Dates
Last Update Posted: November 8, 2023
Last Verified: November 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ApcinteX Ltd:
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Hemophilia B
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Protein C
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action